INTEGRATED BIOPHARMA INC (INBP) stock intrinsic value fair value estimate & owner earnings analysis

Integrated BioPharma is a New Jersey-based contract manufacturer of vitamins, supplements and other nutraceutical products, making tablets and capsules on behalf of other companies' brands through its Manhattan Drug Company subsidiary in Hillside, New Jersey. Revenue was about $54 million in the fiscal year ended June 30, 2025. The business is built around two large customers. Life Extension and Herbalife together made up roughly 84-90% of consolidated sales in recent years, with Life Extension the larger and steadier of the two. Neither relationship carries a minimum-order commitment in either direction -- a structure the company itself describes as typical of how it contracts with all of its manufacturing customers, Life Extension included. The Herbalife agreements expired on December 31, 2025 and were not renewed. That loss is now visible in the numbers: in the quarter that fell entirely after the expiration (January-March 2026), revenue was down about 27% year over year and the company's gross margin, which had run around 10% a year earlier, turned slightly negative. Revenue and profitability had already been softening in the two prior quarters as the contract wound down. This is a real, current, and so far unrecovered deterioration, not a one-quarter blip. The balance sheet is a genuine offset to that risk. The company carries no debt, held about $5.8 million in cash and $12.4 million in working capital as of March 31, 2026, and its bank recently renewed its $4 million revolving credit line for another year, through April 2027. Management has stated it has resources to fund operations at least into May 2027. This is a company under real commercial pressure, not one facing a liquidity crisis. We valued the business using owner earnings -- operating cash flow adjusted to remove working-capital swings and stock compensation, less the capital spending needed just to maintain the business -- built for each of the last eight fiscal years to capture a full demand cycle (pre-pandemic, the pandemic-era surge in immune-health supplement demand, the post-pandemic pullback, and last year's partial rebound). The median of that run, excluding the unrepresentative pandemic peak, describes the business as it existed with Herbalife as a full customer. Because Herbalife is now gone and the interim results show a business that is meaningfully smaller and currently thinner-margin than that history, our near-term forecast starts well below both the historical median and the trailing reported year, not above it, and only rebuilds gradually as the company works to refill capacity. Our base case assumes the company operates at roughly breakeven in the first forecast year, then gradually restores profitability over five to six years as fixed costs are right-sized and some replacement volume is won, eventually returning to a margin similar to its historical median on a smaller revenue base of roughly $50 million rather than the old $54 million. Our bear case (roughly a one-in-ten outcome) assumes the current negative-margin stretch persists for two to three years with no recovery in volume, reflecting the same no-minimum-commitment contract structure that let Herbalife walk away applying equally to the company's remaining major customer; profitability only slowly turns positive and never fully recovers. Our bull case assumes the company successfully wins new contract-manufacturing business, drawing on its own demonstrated history of growing revenue meaningfully within its existing facility, and margins recover to the best level it has sustained outside the pandemic surge. None of these cases assumes anything about the broader market -- they turn entirely on what happens to this company's customer base and capacity utilization. Beyond the ten-year forecast, we assume each case continues at roughly its year-ten level rather than growing further, reflecting the company's long-standing, FDA-registered manufacturing facility and multi-decade customer relationships as the reason cash generation persists, but with no specific evidence to justify assuming continued growth on top of that. That continuation value is about two-thirds of the total in the base and bull cases, which means the valuation depends heavily on the business still existing in a recognizable, and by then stabilized, form a decade from now. Putting it together: our bear case values the shares at roughly $0.15, our base case at roughly $1.02, and our bull case at roughly $1.72. This is a very wide range, and it reflects genuine, currently unresolved uncertainty about whether the lost customer volume gets replaced -- this is not a predictable business right now. Given that width, the small size of the company, and its thin, over-the-counter trading, the margin-of-safety price is set with a large cushion, at approximately $0.24 per share. That price also assumes the fiscal 2026 annual report, expected imminently, confirms that revenue and margins have actually stabilized rather than continuing to erode -- the most recent quarterly data available to us shows the decline still accelerating, not leveling off. One judgment worth noting: the interim financial data shows healthy operating cash flow even as the company reported a net loss, which mainly reflects a temporary cash benefit from shrinking inventory and receivables as the business contracts -- a one-time source of cash, not a sign of improving underlying profitability, and one we have excluded from our forward estimates. We were also not able to review the full narrative discussion in the most recent quarterly filing, only its structured financial data and independently verified figures drawn from it; our reading of what is driving the decline relies on the numbers and the dated contract-expiration fact from the annual report rather than management's own quarter-by-quarter explanation.